西达本胺预处理后化疗的高危难治淋巴系统恶性肿瘤16例  

Chemotherapy after chidamide pretreatment in high-risk and refractory lymphoid malignancy: report of 16 cases

作　　者：黄顺桦 孟凡义 俞亚琴 姚达娜 钟清秀 陈虹羽 王晓果 Huang Shunhua;Meng Fanyi;Yu Yaqin;Yao Dana;Zhong Qingxiu;Chen Hongyu;Wang Xiaoguo(Department of Hemalology, Dongguan Kanghua Hospital, Donggin 523000, China)

机构地区：[1]广东省东莞康华医院血液病中心,523000

出　　处：《白血病．淋巴瘤》2018年第12期750-753,共4页Journal of Leukemia & Lymphoma

摘　　要：目的探讨继西达本胺预处理后化疗的高危、难治淋巴系统恶性肿瘤患者的治疗效果方法对东莞康华医院血液病中心2015年1月至2017年6月采用西达本胺联合化疗治疗继西达本胺预处理3 d后化疗的高危、难治淋巴系统恶性肿瘤16例患者的疗效及不良反应进行分析:结果16例患者中,男性6例,女性10例,中位年龄49.5岁(23 ~ 88岁),既往系统化疗中位疗程4个(0?22个)14例入组该方案诱导化疗患者中,完全缓解(CR )7例,部分缓解(PR )7例.14例患者均获得临床疗效,总有效率(ORR)为100% 2例缓解后进入本方案巩固治疗的患者持续CR随访至2017年12月,中位随访时间为13个月(2~24个月).患者总生存(OS )9例,死亡7例,无进展生存(PFS)9例.继西达本胺预处理后化疗的不良反应常见有胃肠道反应,程度轻且可控.结论继西达本胺预处理后化疗有望提高高危、难治淋巴系统恶性肿瘤患者的治疗效果,改善疾病预后.Objective To analvze the therapeutic effects of chemotherapy after chidamide pretreatment in 16 cases of high-risk and refiacton lymphoid malignancy. Methods The efficacy and adverse reactions of 16 patirnts with high-risk ci nd refractory lymphoid malignancy who received chidamide combined with chemotherapy after 3 days pretreatment of cliidaniidr were analyzed. Results Sixteen patients included 6 males and 1() females, and the meilicin age was 49.5 years old (23-88 years old). The median course of previous systemic c hemotherapy was 4 (range 0-22). Among 14 patients who received induction clieinotherapy. 7 patients achieved coinplrle rrniission (CR), 7 patients achieved partial remission (PR). Fourteen patients had achieved clinical efficacy, and the overall response rate (ORR) was 100 %. After 2 cases had remission , the patients who entered this regimen for consolidation chemotherapy also had duiable CR. The median follow-up time was 13 months (range 2-24 months) until December 2017. Nine cases had overall sun ival (OS). 7 cases died and 9 cases had progression-free sun ival. Common adverse effects of the chemotherapy in eluded mild and controllable gastrointestinal reactions after chidamide. Conclusion Chemolhenipy after chidamide pretreatment may improve the effect and prognosis of high-risk or refractory lymphoid malignancy.

关 键 词：淋巴瘤 药物疗法 联合 西达本胺 高危 难治 

分 类 号：R733[医药卫生—肿瘤]